Psyence Biomedical (NASDAQ:PBM) Issues Earnings Results

Psyence Biomedical (NASDAQ:PBM) posted its quarterly earnings data on Monday. The company reported ($0.40) earnings per share for the quarter, FiscalAI reports.

Psyence Biomedical Stock Performance

NASDAQ PBM opened at $3.10 on Tuesday. Psyence Biomedical has a 52 week low of $1.92 and a 52 week high of $74.94. The stock has a market capitalization of $3.17 million, a price-to-earnings ratio of 0.12 and a beta of 1.64. The stock’s 50 day moving average price is $4.87 and its two-hundred day moving average price is $4.58.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Psyence Biomedical stock. Virtu Financial LLC lifted its stake in shares of Psyence Biomedical Ltd. (NASDAQ:PBM) by 258.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 37,042 shares of the company’s stock after purchasing an additional 26,717 shares during the period. Virtu Financial LLC owned 3.63% of Psyence Biomedical worth $28,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 77.44% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Wall Street Zen upgraded Psyence Biomedical to a “hold” rating in a research report on Saturday, June 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Psyence Biomedical in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Psyence Biomedical Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care.